Delivery Order SPE2DB22D3016-SPE2DB24FAUB7
- Not listed
- This federal contract award, with a value of $56,094.82, was made by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The contract is for the delivery of NURTEC ODT 75 MG TABLET 8S, a pharmaceutical product, to the DLA. This appears to be a firm-fixed price delivery order contract, with a completion date of February 6, 2024. The contract has no set-aside designation, indicating it was awarded through full and open competition. Amerisourcebergen...
- This federal contract award, valued at $76,757.28, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The contract is for the delivery of NURTEC ODT 75 MG TABLET 8S, a pharmaceutical product, with an ultimate completion date of September 2, 2022. The contract type is a Delivery Order with a Firm Fixed Price pricing structure. This award is not designated as a set-aside contract. Amerisourcebergen Drug Corp is a major pharmaceutical...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., for the delivery of NURTEC ODT 75 MG TABLET 8S. The fixed-price delivery order, valued at $21,306.21, has an ultimate completion date of October 24, 2023. Amerisourcebergen Drug Corp is a major pharmaceutical distributor and healthcare solutions provider that plays a critical role in supplying medical products to federal government agencies, particularly the...
- This federal contract award was made by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The contract is a delivery order valued at $31,156.27 for the provision of NURTEC ODT 75 MG TABLET 8S, a pharmaceutical product. The award has an ultimate completion date of January 12, 2024 and is structured as a firm fixed-price contract. This contract is not designated with a set-aside. Amerisourcebergen Drug Corp is a major pharmaceutical distributor that...
- This federal contract award, with a ceiling value of $8,889.64, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of the parent company Cencora, Inc. The contract is a delivery order for the pharmaceutical product NURTEC ODT 75 MG TABLET 8S. This order falls under a larger Indefinite Delivery Contract (IDC) valued at up to $999,999,999.00 that Cencora, Inc. holds with the DLA Troop Support Medical, which serves as the primary vehicle for the company to...
- This federal contract award, valued at $8,193.01, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The contract is a delivery order for the pharmaceutical product NURTEC ODT 75 MG TABLET 8S, with a completion date of January 4, 2024. The contract is a firm fixed-price agreement and does not have a set-aside designation, indicating open competition. Amerisourcebergen Drug Corp is a major pharmaceutical distributor and healthcare...
- This federal contract award is a delivery order from the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the supply of NURTEC ODT 75 MG TABLET 8S. The order, valued at $5,474.98, is part of a larger Indefinite Delivery Contract (IDC) between the DLA Troop Support Medical and Cencora, Inc. (doing business as Amerisourcebergen), worth up to $999,999,999.00 through November 2026. This IDC serves as the primary vehicle for Amerisourcebergen to...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The $21,854.67 firm fixed-price delivery order contract covers the supply of NURTEC ODT 75 MG TABLET 8S, a pharmaceutical product. The contract has an ultimate completion date of February 28, 2024. Amerisourcebergen Drug Corp is a major pharmaceutical distributor and healthcare solutions provider that plays a critical role in supplying medical products to...
- This federal contract award was made by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of the parent company Cencora, Inc. The contract, valued at $4,808.07, is a Delivery Order for the pharmaceutical product NURTEC ODT 75 MG TABLET 8S. The contract has an ultimate completion date of February 28, 2024. Amerisourcebergen Drug Corp is a major pharmaceutical distributor and healthcare solutions provider that plays a critical role in supplying medical products to...
- This federal contract award, valued at $25,171.64, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The contract is for the delivery of NURTEC ODT 75 MG TABLET 8S, a pharmaceutical product. This is an open competition contract with no set-aside designation. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999.00, which serves as the...
- SPE2DB22D3016Indefinite Delivery Contract
- SPE2DB22D3016-SPE2DB24FAUB7Delivery Order
This federal contract award, valued at $20,373.68, was issued by the Defense Logistics Agency (DLA) to the prime contractor, Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The contract is for the delivery of NURTEC ODT 75 MG TABLET 8S, a pharmaceutical product, with a period of performance through May 1, 2024. The contract is a Firm Fixed Price Delivery Order and does not have a set-aside designation, indicating it was awarded through full and open competition. Amerisourcebergen Drug Corp is a major pharmaceutical distributor and healthcare solutions provider that plays a critical role in supplying medical products to federal government agencies, particularly the Department of Defense (DoD) and Department of Veterans Affairs (VA) healthcare systems. The company holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999.00, which serves as the primary vehicle for delivering a comprehensive range of pharmaceutical products and medical supplies to DLA facilities supporting the DoD worldwide.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $20.4k | 4/30/24 |